Arcus Biosciences, Inc.
$28.80
The Read: Arcus Biosciences' stock rallied sharply on strong Q4 2025 results and robust cash supporting its kidney cancer drug casdatifan, but later dipped nearly 7% after Q1 2026 showed a wider-than-expected loss despite revenue beats, while incremental TIGIT data failed to boost shares.
Price
Overlays
Panel
RCUS
Hover to view data
No Data